The leading resource for comprehensive insight and
intelligence on the global psychedelics industry.
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic healthcare industry.
A data and insights platform for the psychedelic healthcare industry.
The Psychedelics as Medicine Report: Third Edition.
200+ pages of industry data and insight empowers investors, operators and regulators to make informed decisions.
Download your complimentary copy:
Psychedelics as Medicine: Third Edition | PSYCH
Download the most comprehensive account of the global psychedelics industry, with unparalleled market intelligence and i...
👏🏼 👏🏼 👏🏼 https://twitter.com/psychglobal_/status/1527624041678262272
Leaders in psychedelic healthcare met at last week's PSYCH Symposium.
@MindMedco's Rob Barrow with Biomind Labs' Alejandro Antalich, @SmallPharma's Carol Routledge and @BeckleyPsytech's Cosmo Feilding Mellen.
Partnership opportunities: https://bit.ly/3wqrMMG
$MNMD $BMND $DMT
'Veterans were given controlled doses of MDMA and 68% experienced complete remission from PTSD.'
As social stigma dissipates, @MAPS' MDMA-assisted therapy for PTSD is set to be regulated in 2023: via @Forbes
Author Post: Psychedelics As Treatment Options For Mental Health
"More and more studies reveal that regulated doses of psychedelics like LSD, psilocybin (magic mushrooms), MDMA, or ...
Thanks @psychglobal_ for an excellent Symposium in London last week. Look forward to our next visit to #EU & #UK as @clairvoyantrx's #psilocybintherapy trial is initiated on each side of the Atlantic shortly
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.
Gain unparalleled market intelligence and insights from thought-leaders and industry experts, identifying lucrative opportunities for investors, operators and regulators.